<p><strong>Vicor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/VICR">VICR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Vicor will report an <strong>earnings per share</strong> (EPS) of $0.20. </p>
<p>Investors in Vicor are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.11, which was followed by a 16.55% increase in the share price the next day.</p>
<p>Here's a look at Vicor's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.18</td>
<td align="right">0.29</td>
<td align="right">0.20</td>
<td align="right">0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.07</td>
<td align="right">0.06</td>
<td align="right">0.23</td>
<td align="right">0.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">17.00</td>
<td align="right">-23.00</td>
<td align="right">23.00</td>
<td align="right">14.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760979400_0.png" alt="eps graph" /></p>

<h3>Stock Performance</h3>
<p>Shares of Vicor were trading at $57.43 as of October 17. Over the last 52-week period, shares are up 33.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VICR/earnings"><strong>To track all earnings releases for Vicor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Vicor's Earnings: A Preview

<p>Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PEGA">PEGA</a>) will release its quarterly earnings report on Tuesday, 2025-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Pegasystems to report an <strong>earnings per share</strong> (EPS) of $0.14.</p>
<p>Pegasystems bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.09, which was followed by a 13.92% increase in the share price the next day.</p>
<p>Here's a look at Pegasystems's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.19</td>
<td align="right">0.23</td>
<td align="right">0.74</td>
<td align="right">0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.28</td>
<td align="right">0.77</td>
<td align="right">0.81</td>
<td align="right">0.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">14.00</td>
<td align="right">29.00</td>
<td align="right">-20.00</td>
<td align="right">15.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760979090_0.png" alt="eps graph" /></p>

<h3>Performance of Pegasystems Shares</h3>
<p>Shares of Pegasystems were trading at $53.38 as of October 17. Over the last 52-week period, shares are up 55.09%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PEGA/earnings"><strong>To track all earnings releases for Pegasystems visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Pegasystems Earnings Preview

<p>Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BCPC">BCPC</a>) is preparing to release its quarterly earnings on Tuesday, 2025-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Balchem to report an <strong>earnings per share</strong> (EPS) of $1.33.</p>
<p>Investors in Balchem are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 0.2% drop in the share price the following trading session.</p>
<p>Here's a look at Balchem's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">1.25</td>
<td align="right">1.22</td>
<td align="right">1.11</td>
<td align="right">1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.27</td>
<td align="right">1.22</td>
<td align="right">1.13</td>
<td align="right">1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">0.00</td>
<td align="right">0.00</td>
<td align="right">1.00</td>
<td align="right">3.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760978873_0.png" alt="eps graph" /></p>

<h3>Tracking Balchem's Stock Performance</h3>
<p>Shares of Balchem were trading at $147.59 as of October 17. Over the last 52-week period, shares are down 11.33%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BCPC/earnings"><strong>To track all earnings releases for Balchem visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Balchem's Earnings Outlook

<p>Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BMI">BMI</a>) will release its quarterly earnings report on Tuesday, 2025-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Badger Meter to report an <strong>earnings per share</strong> (EPS) of $1.13.</p>
<p>Anticipation surrounds Badger Meter's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.05, which was followed by a 6.25% drop in the share price the next day.</p>
<p>Here's a look at Badger Meter's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">1.22</td>
<td align="right">1.05</td>
<td align="right">1.10</td>
<td align="right">1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.17</td>
<td align="right">1.30</td>
<td align="right">1.04</td>
<td align="right">1.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-6.00</td>
<td align="right">10.00</td>
<td align="right">3.00</td>
<td align="right">1.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760978657_0.png" alt="eps graph" /></p>

<h3>Performance of Badger Meter Shares</h3>
<p>Shares of Badger Meter were trading at $179.94 as of October 17. Over the last 52-week period, shares are down 6.31%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BMI/earnings"><strong>To track all earnings releases for Badger Meter visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

A Preview Of Badger Meter's Earnings

<p>In the current session, the stock is trading at $145.99, after a <strong>0.05%</strong> spike. Over the past month, <strong>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/XYL">XYL</a>)</strong> stock increased by <strong>2.01%</strong>, and in the past year, by <strong>11.13%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p><p><img src="https://www.benzinga.com/files/images/story/2025/1760978528_0.png" alt="Past Year Chart" /></p></p>
<h3>Xylem P/E Ratio Analysis in Relation to Industry Peers</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of <strong>28.72</strong> in the Machinery industry, Xylem Inc. has a higher P/E ratio of <strong>38.0</strong>. Shareholders might be inclined to think that Xylem Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p><p><img src="https://www.benzinga.com/files/images/story/2025/1760978528_1.png" alt="Guage" /></p></p>
<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>

P/E Ratio Insights for Xylem

<p><strong>Valmont Industries</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/VMI">VMI</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Valmont Industries will report an <strong>earnings per share</strong> (EPS) of $4.63. </p>
<p>Anticipation surrounds Valmont Industries's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.12, which was followed by a 1.38% increase in the share price the next day.</p>
<p>Here's a look at Valmont Industries's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">4.76</td>
<td align="right">4.36</td>
<td align="right">3.62</td>
<td align="right">4.00</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">4.88</td>
<td align="right">4.32</td>
<td align="right">3.84</td>
<td align="right">4.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">1.00</td>
<td align="right">3.00</td>
<td align="right">-3.00</td>
<td align="right">10.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760978221_0.png" alt="eps graph" /></p>

<h3>Valmont Industries Share Price Analysis</h3>
<p>Shares of Valmont Industries were trading at $404.86 as of October 17. Over the last 52-week period, shares are up 36.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Valmont Industries</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Valmont Industries.</p>
<p>With 3 analyst ratings, Valmont Industries has a consensus rating of Buy. The average one-year price target is $443.33, indicating a potential 9.5% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Fluor, Dycom Industries and Primoris Services, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Fluor, with an average 1-year price target of $56.2, suggesting a potential 86.12% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dycom Industries, with an average 1-year price target of $304.11, suggesting a potential 24.89% downside.</li>
<li>Analysts currently favor an Buy trajectory for Primoris Services, with an average 1-year price target of $136.15, suggesting a potential 66.37% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Fluor, Dycom Industries and Primoris Services, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valmont Industries</td>
<td>Buy</td>
<td>1.04%</td>
<td>$321.17M</td>
<td>-1.91%</td>
</tr>
<tr>
<td>Fluor</td>
<td>Buy</td>
<td>-5.89%</td>
<td>$56M</td>
<td>51.57%</td>
</tr>
<tr>
<td>Dycom Industries</td>
<td>Buy</td>
<td>14.54%</td>
<td>$307.49M</td>
<td>7.40%</td>
</tr>
<tr>
<td>Primoris Services</td>
<td>Buy</td>
<td>20.91%</td>
<td>$231.74M</td>
<td>5.66%</td>
</tr>
</tbody>
</table></p>
<p>Key Takeaway:</p>
<p>Valmont Industries ranks first in revenue growth among its peers. It ranks last in gross profit. It ranks last in return on equity.</p>
<h3>About Valmont Industries</h3>
<p>Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.</p>
<h3>Key Indicators: Valmont Industries's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Valmont Industries's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately <strong>1.04%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Valmont Industries's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-2.88%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Valmont Industries's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-1.91%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Valmont Industries's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.9%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Valmont Industries's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.56</strong>.</p>
<p><a href="https://www.benzinga.com/quote/VMI/earnings"><strong>To track all earnings releases for Valmont Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Insights Ahead: Valmont Industries's Quarterly Earnings

<p><strong>Bloom Energy Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BE">BE</a>) is energizing investor interest with a bold partnership poised to reshape AI infrastructure. The company is scheduled to release its third-quarter 2025 financial <a href="https://www.benzinga.com/pressreleases/25/10/b48137890/bloom-energy-to-announce-third-quarter-2025-financial-results-on-october-28-2025" target="_blank" rel="noreferrer noopener">results on Oct. 28</a>.</p>



<p>Analysts estimate <a target="_blank" href="https://www.benzinga.com/quote/BE/earnings" rel="noreferrer noopener">adjusted earnings of $0.091</a>, with sales of $425.55 million, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.</p>



<p>Last week, Bloom Energy announced a $5 billion partnership with <strong>Brookfield Asset Management Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BAM">BAM</a>) to implement a reimagined future for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/10/b48171963/brookfield-and-bloom-energy-announce-5-billion-strategic-ai-infrastructure-partnership" rel="noreferrer noopener">AI infrastructure</a>.</p>



<p>Brookfield will invest the amount to deploy Bloom's technology, with global AI factory projects underway, including a European site to be announced by year-end.</p>



<p>Bloom Energy's fuel cells provide clean, scalable onsite power, while Brookfield brings infrastructure and financing expertise. Together, they aim to transform AI factory <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/10/48174221/brookfields-5-billion-bet-powers-bloom-energys-ai-factory-role" rel="noreferrer noopener">design and power</a>.</p>



<p>Bank Of America (BofA) Securities analyst Dimple Gosai on Monday wrote, &#8220;Bloom&#8217;s new Brookfield partnership adds a blue-chip counterparty and reinforces its position at the center of the AI-driven power-resiliency build-out.&#8221;</p>



<p>BofA increased price forecast from $24 to $26, with <a target="_blank" href="https://www.benzinga.com/quote/BE/analyst-ratings" rel="noreferrer noopener">an Underperform rating</a>.</p>



<p>Gosai expects initial deployments to ramp up gradually, not driving near-term earnings. However, the stock's rally suggests investors are already pricing in the potential Brookfield earnings as an executable backlog.</p>



<p>&#8220;A strategic win, yes-but the market is paying today for a decade of delivery,&#8221; the analyst added.</p>



<p><strong>Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46326883/fuel-cell-tax-perk-could-supercharge-bloom-energy-in-2026-says-jpmorgan" target="_blank" rel="noreferrer noopener">Fuel Cell Tax Perk Could Supercharge Bloom Energy In 2026, Says JPMorgan</a></strong></p>



<p>BofA expects the third quarter earnings call to focus on cadence and cost rather than new deal headlines-updates on AEP order flow, Brookfield&#8217;s first-site timeline, and&nbsp;&nbsp;<strong>Oracle Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ORCL">ORCL</a>) <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46610808/bloom-energy-stock-jumps-on-deal-to-power-oracles-ai-data-centers" rel="noreferrer noopener">deployment will be key</a>.</p>



<p>Gosai looks for reaffirmation of 2025 guidance, alongside commentary on margin trajectory, CFO search progress, capacity-doubling plans, and capital below consensus.</p>



<p>Bloom Energy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46773977/bloom-energy-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">reaffirmed 2025 revenue</a> guidance of $1.65 billion-$1.85 billion versus consensus of $1.74 billion.</p>



<p>For 2025, BofA forecasts $1.72 billion of revenue and $199 million of EBITDA at a 28.2% margin-the low end of management&#8217;s guide and below Street expectations ($1.77 billion / 29.3% / $212 million).</p>



<p>BofA says the numbers reflect a more measured pace of margin improvement and order realization.</p>



<p><strong>BE Price Action:</strong>&nbsp;Bloom shares are up 2.60% at $114.40 at the time of publication on Monday. </p>



<p><strong>Read Next</strong>:</p>



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/10/48299073/alibaba-leads-goldmans-top-chinese-picks-for-global-growth" target="_blank" rel="noreferrer noopener"><strong>Alibaba Leads Goldman&#8217;s Top Chinese Picks For Global Growth</strong></a></li>
</ul>



<p><em>Photo by Michael Vi via Shutterstock</em></p>

Bloom Energy's Brookfield Deal Brings Prestige, Not Profit—Yet

<p>Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/PNR">PNR</a>) will release its quarterly earnings report on Tuesday, 2025-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Pentair to report an <strong>earnings per share</strong> (EPS) of $1.18.</p>
<p>The announcement from Pentair is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 1.18% drop in the share price on the subsequent day.</p>
<p>Here's a look at Pentair's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">1.33</td>
<td align="right">1.01</td>
<td align="right">1.02</td>
<td align="right">1.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.39</td>
<td align="right">1.11</td>
<td align="right">1.08</td>
<td align="right">1.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-1.00</td>
<td align="right">2.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760977906_0.png" alt="eps graph" /></p>

<h3>Performance of Pentair Shares</h3>
<p>Shares of Pentair were trading at $108.79 as of October 17. Over the last 52-week period, shares are up 11.02%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Pentair</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Pentair.</p>
<p>The consensus rating for Pentair is Outperform, based on 10 analyst ratings. With an average one-year price target of $119.0, there's a potential 9.39% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Snap-on, Fortive and Graco, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Snap-on, with an average 1-year price target of $365.0, suggesting a potential 235.51% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Fortive, with an average 1-year price target of $53.67, suggesting a potential 50.67% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Graco, with an average 1-year price target of $91.0, suggesting a potential 16.35% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Snap-on, Fortive and Graco, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentair</td>
<td>Outperform</td>
<td>2.17%</td>
<td>$456.60M</td>
<td>4.07%</td>
</tr>
<tr>
<td>Snap-on</td>
<td>Outperform</td>
<td>3.57%</td>
<td>$674.80M</td>
<td>4.60%</td>
</tr>
<tr>
<td>Fortive</td>
<td>Neutral</td>
<td>-2.16%</td>
<td>$895.70M</td>
<td>1.62%</td>
</tr>
<tr>
<td>Graco</td>
<td>Neutral</td>
<td>3.36%</td>
<td>$299.53M</td>
<td>5.13%</td>
</tr>
</tbody>
</table></p>
<p>Key Takeaway:</p>
<p>Pentair ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus and Return on Equity.</p>
<h3>About Pentair</h3>
<p>Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.</p>
<h3>Pentair's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pentair displayed positive results in 3 months. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately <strong>2.17%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Pentair's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>13.22%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>4.07%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pentair's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.41</strong>, Pentair adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/PNR/earnings"><strong>To track all earnings releases for Pentair visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Pentair Earnings Preview

<p><strong>PACCAR</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PCAR">PCAR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that PACCAR will report an <strong>earnings per share</strong> (EPS) of $1.14. </p>
<p>PACCAR bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.03, leading to a 2.57% increase in the share price the following trading session.</p>
<p>Here's a look at PACCAR's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">1.34</td>
<td align="right">1.59</td>
<td align="right">1.69</td>
<td align="right">1.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.37</td>
<td align="right">1.46</td>
<td align="right">1.66</td>
<td align="right">1.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">-1.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760977569_0.png" alt="eps graph" /></p>

<h3>Market Performance of PACCAR's Stock</h3>
<p>Shares of PACCAR were trading at $94.69 as of October 17. Over the last 52-week period, shares are down 7.16%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on PACCAR</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding PACCAR.</p>
<p>A total of  analyst ratings have been received for PACCAR, with the consensus rating being . The average one-year price target stands at $, suggesting a potential .</p>
<p><a href="https://www.benzinga.com/quote/PCAR/earnings"><strong>To track all earnings releases for PACCAR visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

A Preview Of PACCAR's Earnings

<p>Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/JCI">JCI</a>) has outperformed the market over the past 15 years by 1.54% on an annualized basis producing an average annual return of 13.78%. Currently, Johnson Controls Intl has a market capitalization of $72.52 billion. </p>
<p><strong>Buying $100 In JCI:</strong> If an investor had bought $100 of JCI stock 15 years ago, it would be worth <strong>$688.07</strong> today based on a price of $109.86 for JCI at the time of writing.</p>
<h3>Johnson Controls Intl's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760977563_0.png" alt="comp_fig" /></p>

<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Here's How Much $100 Invested In Johnson Controls Intl 15 Years Ago Would Be Worth Today

<p>EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/EQT">EQT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that EQT will report an <strong>earnings per share</strong> (EPS) of $0.42.</p>
<p>EQT bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 4.38% drop in the share price on the following day.</p>
<p>Here's a look at EQT's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.43</td>
<td align="right">1.02</td>
<td align="right">0.53</td>
<td align="right">0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.45</td>
<td align="right">1.18</td>
<td align="right">0.69</td>
<td align="right">0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-4.00</td>
<td align="right">0.00</td>
<td align="right">1.00</td>
<td align="right">3.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760977211_0.png" alt="eps graph" /></p>

<h3>Tracking EQT's Stock Performance</h3>
<p>Shares of EQT were trading at $54.08 as of October 17. Over the last 52-week period, shares are up 56.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EQT/earnings"><strong>To track all earnings releases for EQT visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Earnings Preview For EQT

<p>Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/DGX">DGX</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Quest Diagnostics will report an <strong>earnings per share</strong> (EPS) of $2.51.</p>
<p>Anticipation surrounds Quest Diagnostics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.05 in the last quarter, leading to a 4.35% drop in the share price on the following day.</p>
<p>Here's a look at Quest Diagnostics's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">2.57</td>
<td align="right">2.15</td>
<td align="right">2.18</td>
<td align="right">2.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">2.62</td>
<td align="right">2.21</td>
<td align="right">2.23</td>
<td align="right">2.30</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-4.00</td>
<td align="right">0.00</td>
<td align="right">-1.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760976988_0.png" alt="eps graph" /></p>

<h3>Performance of Quest Diagnostics Shares</h3>
<p>Shares of Quest Diagnostics were trading at $189.51 as of October 17. Over the last 52-week period, shares are up 20.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DGX/earnings"><strong>To track all earnings releases for Quest Diagnostics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

A Glimpse of Quest Diagnostics's Earnings Potential

<p>Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/REGN">REGN</a>) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently, Regeneron Pharmaceuticals has a market capitalization of $62.41 billion. </p>
<p><strong>Buying $1000 In REGN:</strong> If an investor had bought $1000 of REGN stock 20 years ago, it would be worth <strong>$52,709.32</strong> today based on a price of $578.05 for REGN at the time of writing.</p>
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760976894_0.png" alt="comp_fig" /></p>

<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

<p>Shares of <strong>Replimune Group, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/REPL">REPL</a>) are rising Monday after the clinical stage biotechnology company shared an <a href="https://www.benzinga.com/news/25/10/48304978/leerink-partners-upgrades-replimune-group-to-outperform-raises-price-target-to-13">important regulatory update</a>. </p>



<ul class="wp-block-list">
<li><em>REPL is charging ahead with explosive momentum. <a href="https://www.benzinga.com/quote/REPL" target="_blank" rel="noreferrer noopener">Stay ahead of the curve here.</a></em></li>
</ul>



<p><strong>What To Know: </strong>Replimune said the <strong>U.S. Food and Drug Administration</strong> (FDA) has accepted the resubmission of its biologics license application (BLA) for RP1 in combination with nivolumab. RP1 is Replimune&#8217;s lead product candidate intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.</p>



<p>The BLA for RP1 in combination with nivolumab is for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. </p>



<p>The deadline for the FDA to make a decision on Replimune&#8217;s new drug application is next April. During the past few months, Replimune has been working to address agency feedback. Additional information, data and analyses were included in the resubmission, which will be part of the BLA review.</p>



<p>"We are pleased the agency has accepted the resubmission of our BLA for&nbsp;RP1," said&nbsp;<strong>Sushil Patel</strong>, CEO of&nbsp;Replimune. "RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy. We look forward to working closely with the agency to expedite this review as much as possible for patients' benefit."</p>



<p>Following the FDA acceptance of the company&#8217;s BLA resubmission, Wedbush analyst Robert Driscoll upgraded Replimune from Neutral to Outperform and raised the price target from $4 to $18. Leerink Partners also upgraded the stock from Market Perform to Outperform and raised the price target from $3 to $13. The positive analyst coverage appears to be helping boost shares on Monday.</p>



<p><strong>REPL Analysis:</strong> Despite Monday&#8217;s gains, Replimune&#8217;s year-to-date performance remains down more than 20%, suggesting that the stock has faced challenges throughout the year. Its current setup suggests that if the stock can maintain its momentum and break through psychological resistance at $10.00, it may pave the way for a challenge towards the 52-week high. Conversely, a pullback towards the 50-day moving average could provide a critical test of support, determining the stock&#8217;s ability to sustain its recent gains.</p>



<p><strong>REPL Price Action: </strong>Replimune shares were up 116.32% at $9.73 at the time of publication on Monday, <a href="https://pro.benzinga.com/">according to Benzinga Pro</a>. The stock is trading within its 52-week range of $2.68 to $17.00, reflecting a significant surge from its previous close of $4.50.</p>



<p><strong>Read Next:</strong></p>



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/10/48304072/ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday"><strong>WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday</strong></a></li>
</ul>



<p><em>Image: Shutterstock</em></p>

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

<p>Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HAL">HAL</a>) will release its quarterly earnings report on Tuesday, 2025-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Halliburton to report an <strong>earnings per share</strong> (EPS) of $0.50.</p>
<p>The market awaits Halliburton's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 2.71% increase in the share price the next day.</p>
<p>Here's a look at Halliburton's past performance and the resulting price change:</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
<th align="right"><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.56</td>
<td align="right">0.6</td>
<td align="right">0.7</td>
<td align="right">0.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.55</td>
<td align="right">0.6</td>
<td align="right">0.7</td>
<td align="right">0.73</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">3.00</td>
<td align="right">0.0</td>
<td align="right">-2.0</td>
<td align="right">-1.00</td>
</tr>
</tbody>
</table></p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1760976738_0.png" alt="eps graph" /></p>

<h3>Market Performance of Halliburton's Stock</h3>
<p>Shares of Halliburton were trading at $22.27 as of October 17. Over the last 52-week period, shares are down 20.66%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Halliburton</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Halliburton.</p>
<p>With 11 analyst ratings, Halliburton has a consensus rating of Neutral. The average one-year price target is $25.27, indicating a potential 13.47% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of TechnipFMC, NOV and Weatherford International, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for TechnipFMC, with an average 1-year price target of $45.0, suggesting a potential 102.07% upside.</li>
<li>Analysts currently favor an Neutral trajectory for NOV, with an average 1-year price target of $16.0, suggesting a potential 28.15% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Weatherford International, with an average 1-year price target of $80.83, suggesting a potential 262.95% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for TechnipFMC, NOV and Weatherford International are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halliburton</td>
<td>Neutral</td>
<td>-5.54%</td>
<td>$819M</td>
<td>4.52%</td>
</tr>
<tr>
<td>TechnipFMC</td>
<td>Outperform</td>
<td>8.99%</td>
<td>$593.30M</td>
<td>8.52%</td>
</tr>
<tr>
<td>NOV</td>
<td>Neutral</td>
<td>-1.26%</td>
<td>$446M</td>
<td>1.67%</td>
</tr>
<tr>
<td>Weatherford International</td>
<td>Outperform</td>
<td>-14.31%</td>
<td>$375M</td>
<td>9.50%</td>
</tr>
</tbody>
</table></p>
<p>Key Takeaway:</p>
<p>Halliburton ranks at the bottom for Revenue Growth with a negative percentage. It is in the middle for Gross Profit. Halliburton is at the bottom for Return on Equity.</p>
<h3>Delving into Halliburton's Background</h3>
<p>Halliburton is North America's largest oilfield service company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. The firm's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been homed in over a century of operations.</p>
<h3>Halliburton's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Halliburton's financials over 3 months reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately <strong>-5.54%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Halliburton's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.57%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Halliburton's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.52%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Halliburton's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.87%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Halliburton's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.81</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/HAL/earnings"><strong>To track all earnings releases for Halliburton visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

Principais histórias